Oncology

#Collaboration #Drug discovery #Oncology

Drug discovery collaboration to progress inhibitor project  

Domainex has supported the collaboration between Queen’s University Belfast (UK) and Ipsen to research, develop, manufacture and commercialise FLIP inhibitors – a programme that Domainex has supported since its inception.  Background  At the start of the project, Domainex conducted a LeadBuilder virtual screen that generated the initial hit matter. Read More

#News

Human liver
#Clinical trials #Liver disease #Oncology #Therapeutics #Tumours

First patient dosed in advanced liver cancer clinical trial 

MiNA Therapeutics has dosed the first patient in a global Phase II clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer).  What is OUTREACH-2?  OUTREACH-2 is a multi-centre,… Read More

#News #Trending News

#Cancer immunotherapy #Immunotherapy #Liver disease #Oncology

Immunotherapy before surgery in liver cancer patients can kill the tumour  

In a clinical trial, Mount Sinai scientists gave immunotherapy to liver cancer patients before they received surgery and found that tumours died off significantly before surgery in a third of the patients, according to results reported in The Lancet Gastroenterology and Hepatology.   The results  The researchers… Read More

#News #Trending News

#Acquisition #Collaboration #Oncology #T-Cells #Therapeutics

Takeover plan looks to develop T cell engager therapies 

Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.   The acquisition   Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are… Read More

#News

Lung cancer
#AstraZeneca #Lung cancer #Oncology

Success for AstraZeneca lung cancer therapy 

AstraZeneca’s Tagrisso (osimertinib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.1  Context  Lung… Read More

#News #Trending News

#Cancer research #Clinical trials #Drug development #Molecular research #Oncology #Personalised medicine

Exclusive: The personalised medicine paradigm

Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation… Read More

#Editor's Choice #Exclusive Content #News

#Cancer immunotherapy #Collaboration #Drug design #Drug targets #Oncology

Collaboration will investigate next-generation cancer therapies 

PhoreMost, a UK-based biopharmaceutical company developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, have collaborated to study oncology targets currently considered undruggable.   The agreement  The POLARISqb Tachyon quantum computing platform will be used to scan billions of… Read More

#News

#Biosciences #Cancer research #Drug development #Drug discovery #Oncology #Precision medicine

Anticancer Bioscience expands to Chinese biotech research park 

Anticancer Bioscience, a company developing synthetic lethal approaches to precision oncology, have relocated to Tianfu International Biotown, in Chengdu, China, to accommodate its growth and expansion, and on the back of its recent financing. Biotown is considered the premier biotech research park in Chengdu, the capital of Sichuan province.  The… Read More

#News

#Brain disease #Cancer #Oncology #Small molecules #Therapeutics #Tumours

Hemispherian’s epigenetic therapeutics act on a new mechanism of action

Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise.  LR: What it does Hemispherian do?  ZA: We are focused on developing a novel class of small molecule drugs (GLIX)… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Cancer research #Clinical trials #Drug discovery #Oncology #T-Cells #Tumours

HOOKIPA advances to Phase II trials for treatment of head and neck cancer 

HOOKIPA Pharma is advancing HB-201 to Phase II to be evaluated in combination with pembrolizumab as first or second-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).   Interim Phase I data in heavily pre-treated patients continue to show HB-200 monotherapy (both… Read More

#News

#Cancer research #Lung cancer #Oncology

Scottish milestone for potential lung cancer treatment 

AstraZeneca’s Tagrisso (osimertinib) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium (SMC) for the treatment of early-stage lung cancer.   Osimertinib will be used as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have… Read More

#Cancer Research #News #Trending News

#Cancer research #Oncology

Merck exclusive: Oncology insight  

Doina Ionescu, General Manager for the UK & Ireland at Merck, talks with DDW’s Megan Thomas about Merck’s innovations in the oncology sector, her thoughts on the future opportunities in the sector, as well some trade secrets and more.  MT: The company has expertise in the oncology space – what innovations can… Read More

#Cancer Research #Exclusive Content #Opinion

#CAR-T #Oncology

Preclinical CAR T proof-of-concept data presented

Elicera Therapeutics, a Swedish clinical stage cell and gene therapy company that develops immuno-oncological treatments focusing on CAR T-cells and oncolytic viruses, has presented preclinical proof-of-concept data for the company’s iTANK-platform at the ESGCT (European Society of Gene & Cell Therapy) Virtual Congress 2021.  iTANK (immunoTherapies Activated with NAP for efficient… Read More

#News

#Cancer research #In vitro #Oncology #Tumour biology

Self-assembling PeptiGels as a platform to recapitulate the tumour microenvironment in pancreatic cancer 

This paid-for advertorial by Manchester BioGel appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   Communication of cells with their microenvironment is vital in understanding intracellular processes. Most matrices lack the mechanical and biochemical tuneability necessary to recreate the cancer microenvironment. Read More

#Exclusive Content

#Drug discovery #Oncology #Organ-on-a-chip

CN Bio service offers support for oncology drug discovery

CN Bio has launched an oncology service which it says is in response to the global need to improve cancer drug discovery approval rates.  Understanding the relationship between pharmacokinetics, pharmacodynamics (PK/PD) and efficacy is critical to the successful development of new medicines, but at present this relationship is primarily investigated using… Read More

#News